FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085901099> ?p ?o ?g. }

• W3085901099 abstract "Abstract Background Early and appropriate antibiotic dosing is associated with improved clinical outcomes in critically ill patients, yet target attainment remains a challenge. Traditional antibiotic dosing is not suitable in critically ill patients, since these patients undergo physiological alterations that strongly affect antibiotic exposure. For beta-lactam antibiotics, the unbound plasma concentrations above at least one to four times the minimal inhibitory concentration (MIC) for 100% of the dosing interval (100%ƒT > 1–4×MIC) have been proposed as pharmacodynamic targets (PDTs) to maximize bacteriological and clinical responses. The objectives of this study are to describe the PDT attainment in critically ill patients and to identify risk factors for target non-attainment. Methods This prospective observational study was performed in two ICUs in the Netherlands. We enrolled adult patients treated with the following beta-lactam antibiotics: amoxicillin (with or without clavulanic acid), cefotaxime, ceftazidime, ceftriaxone, cefuroxime, and meropenem. Based on five samples within a dosing interval at day 2 of therapy, the time unbound concentrations above the epidemiological cut-off (ƒT > MIC ECOFF and ƒT > 4×MIC ECOFF ) were determined. Secondary endpoints were estimated multivariate binomial and binary logistic regression models, for examining the association of PDT attainment with patient characteristics and clinical outcomes. Results A total of 147 patients were included, of whom 63.3% achieved PDT of 100%ƒT > MIC ECOFF and 36.7% achieved 100%ƒT > 4×MIC ECOFF . Regression analysis identified male gender, estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m 2 , and high body mass index (BMI) as risk factors for target non-attainment. Use of continuous renal replacement therapy (CRRT) and high serum urea significantly increased the probability of target attainment. In addition, we found a significant association between the 100%ƒT > MIC ECOFF target attainment and ICU length of stay (LOS), but no significant correlation was found for the 30-day survival. Conclusions Traditional beta-lactam dosing results in low target attainment in the majority of critically ill patients. Male gender, high BMI, and high eGFR were significant risk factors for target non-attainment. These predictors, together with therapeutic drug monitoring, may help ICU clinicians in optimizing beta-lactam dosing in critically ill patients. Trial registration Netherlands Trial Registry (EXPAT trial), NTR 5632 . Registered on 7 December 2015." @default.
• W3085901099 created "2020-09-21" @default.
• W3085901099 creator A5002674457 @default.
• W3085901099 creator A5003841607 @default.
• W3085901099 creator A5008497236 @default.
• W3085901099 creator A5016645171 @default.
• W3085901099 creator A5029528977 @default.
• W3085901099 creator A5030368885 @default.
• W3085901099 creator A5047108361 @default.
• W3085901099 creator A5048764247 @default.
• W3085901099 creator A5070415771 @default.
• W3085901099 creator A5089595715 @default.
• W3085901099 date "2020-09-15" @default.
• W3085901099 modified "2023-10-03" @default.
• W3085901099 title "Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)" @default.
• W3085901099 cites W1971624521 @default.
• W3085901099 cites W1982910325 @default.
• W3085901099 cites W1990063730 @default.
• W3085901099 cites W1996134595 @default.
• W3085901099 cites W2015225568 @default.
• W3085901099 cites W2017331060 @default.
• W3085901099 cites W2023392621 @default.
• W3085901099 cites W2027169933 @default.
• W3085901099 cites W2034644397 @default.
• W3085901099 cites W2046281708 @default.
• W3085901099 cites W2054938569 @default.
• W3085901099 cites W2056612376 @default.
• W3085901099 cites W2057226149 @default.
• W3085901099 cites W2060029296 @default.
• W3085901099 cites W2062495428 @default.
• W3085901099 cites W2063909696 @default.
• W3085901099 cites W2064358970 @default.
• W3085901099 cites W2067772057 @default.
• W3085901099 cites W2076149452 @default.
• W3085901099 cites W2080374429 @default.
• W3085901099 cites W2096348997 @default.
• W3085901099 cites W2099916537 @default.
• W3085901099 cites W2101416655 @default.
• W3085901099 cites W2102663241 @default.
• W3085901099 cites W2111805706 @default.
• W3085901099 cites W2113717321 @default.
• W3085901099 cites W2125699736 @default.
• W3085901099 cites W2131171455 @default.
• W3085901099 cites W2142365884 @default.
• W3085901099 cites W2144045506 @default.
• W3085901099 cites W2153641174 @default.
• W3085901099 cites W2153655781 @default.
• W3085901099 cites W2165158988 @default.
• W3085901099 cites W2165839757 @default.
• W3085901099 cites W2345060422 @default.
• W3085901099 cites W2547781899 @default.
• W3085901099 cites W2576933161 @default.
• W3085901099 cites W2584388311 @default.
• W3085901099 cites W2610730883 @default.
• W3085901099 cites W2621049254 @default.
• W3085901099 cites W2622161734 @default.
• W3085901099 cites W2735133396 @default.
• W3085901099 cites W2766636752 @default.
• W3085901099 cites W2770610803 @default.
• W3085901099 cites W2771362836 @default.
• W3085901099 cites W2886772901 @default.
• W3085901099 cites W2911620641 @default.
• W3085901099 cites W2923845811 @default.
• W3085901099 cites W2991309920 @default.
• W3085901099 cites W3001281146 @default.
• W3085901099 doi "https://doi.org/10.1186/s13054-020-03272-z" @default.
• W3085901099 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7493358" @default.
• W3085901099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32933574" @default.
• W3085901099 hasPublicationYear "2020" @default.
• W3085901099 type Work @default.
• W3085901099 sameAs 3085901099 @default.
• W3085901099 citedByCount "59" @default.
• W3085901099 countsByYear W30859010992021 @default.
• W3085901099 countsByYear W30859010992022 @default.
• W3085901099 countsByYear W30859010992023 @default.
• W3085901099 crossrefType "journal-article" @default.
• W3085901099 hasAuthorship W3085901099A5002674457 @default.
• W3085901099 hasAuthorship W3085901099A5003841607 @default.
• W3085901099 hasAuthorship W3085901099A5008497236 @default.
• W3085901099 hasAuthorship W3085901099A5016645171 @default.
• W3085901099 hasAuthorship W3085901099A5029528977 @default.
• W3085901099 hasAuthorship W3085901099A5030368885 @default.
• W3085901099 hasAuthorship W3085901099A5047108361 @default.
• W3085901099 hasAuthorship W3085901099A5048764247 @default.
• W3085901099 hasAuthorship W3085901099A5070415771 @default.
• W3085901099 hasAuthorship W3085901099A5089595715 @default.
• W3085901099 hasBestOaLocation W30859010991 @default.
• W3085901099 hasConcept C111113717 @default.
• W3085901099 hasConcept C112705442 @default.
• W3085901099 hasConcept C126322002 @default.
• W3085901099 hasConcept C177713679 @default.
• W3085901099 hasConcept C188816634 @default.
• W3085901099 hasConcept C2776968632 @default.
• W3085901099 hasConcept C2777288759 @default.
• W3085901099 hasConcept C2777514703 @default.
• W3085901099 hasConcept C2777637488 @default.
• W3085901099 hasConcept C2779375183 @default.
• W3085901099 hasConcept C501593827 @default.
• W3085901099 hasConcept C523546767 @default.
• W3085901099 hasConcept C54355233 @default.

• next